Smoking motivations and quitting motivations among HIV-infected smokers.

Abstract:

BACKGROUND:The aim of this study was to examine smoking motivation and motivation to quit, and determinants of these motivations among HIV-infected cigarette smokers. METHODS:We conducted a 1-day cross-sectional survey on cigarette smoking in a representative sample of HIV-infected outpatients of French hospitals. A cluster analysis was used to characterize respondents' smoking motivation. A logistic regression was performed to study the factors associated with motivation to quit, including the clusters describing smoking motives. RESULTS:We found four clusters of smoking motivation. These included intellectual/emotional support (22% of respondents), automatic/stress relief (22%; characterized by heavy smoking and strong dependency); weight control (29%; characterized by frequent symptoms of fat accumulation because of antiretroviral therapy) and pleasure/conviviality (27%; corresponding to 'lighter' smokers). In the logistic regression model, among other significant covariates (cigarette consumption level, tobacco dependence and perceived risk of developing a smoking-related disease), the automatic/stress relief cluster was negatively correlated to the motivation to quit (odds ratio 0.39), whereas the weight control cluster was strongly associated to this motivation (odds ratio 2.87). CONCLUSIONS:The diversity of HIV-infected smokers' profiles suggests that different types of anti-tobacco measures should be implemented in this population, such as information campaigns on specific risks incurred by HIV-infected smokers, non-specific and comprehensive measures for those for whom smoking is combined with other difficulties, and alternative therapeutic solutions for those who smoke to deal with lipodystrophy.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Peretti-Watel P,Garelik D,Baron G,Spire B,Ravaud P,Duval X,EVIT Study Group.

doi

10.3851/IMP1292

subject

Has Abstract

pub_date

2009-01-01 00:00:00

pages

781-7

issue

6

eissn

1359-6535

issn

2040-2058

journal_volume

14

pub_type

杂志文章
  • A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings.

    abstract::This article describes the development of a novel sequential sampling method for the surveillance of transmitted HIV drug resistance by cross-sectional survey. Two commonly used sequential sampling methods are described and their applicability to the problem of classifying the prevalence of transmitted HIV drug resist...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Myatt M,Bennett DE

    更新日期:2008-01-01 00:00:00

  • CD4(+) T-cell recovery after initiation of antiretroviral therapy in a resource-limited setting: a prospective cohort analysis.

    abstract:BACKGROUND:CD4(+) T-cell count recovery after antiretroviral therapy (ART) initiation is associated with improved health outcomes. It is unknown how the CD4(+) T-cell counts of African HIV patients recover following ART initiation. METHODS:We examined CD4(+) T-cell count recovery in a large cohort of HIV-positive pati...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2670

    authors: Kanters S,Nachega J,Funk A,Mukasa B,Montaner JS,Ford N,Bucher HC,Mills EJ

    更新日期:2014-01-01 00:00:00

  • HIV type-1 transmission dynamics in recent seroconverters: relationship with transmission of drug resistance and viral diversity.

    abstract:BACKGROUND:HIV type-1 (HIV-1) has been shown to be frequently transmitted by acutely infected patients. We investigated the relationship between the dynamics of HIV-1 transmission within recently infected patients, the HIV-1 variability and the transmission of antiretroviral drug resistance. METHODS:We included patien...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Recordon-Pinson P,Anies G,Bruyand M,Neau D,Morlat P,Pellegrin JL,Groppi A,Thiébaut R,Dabis F,Fleury H,Masquelier B,ANRS CO3 Aquitaine Cohort.

    更新日期:2009-01-01 00:00:00

  • Active pharmaceutical ingredients for antiretroviral treatment in low- and middle-income countries: a survey.

    abstract::Active pharmaceutical ingredients (APIs) are the molecular entities that exert the therapeutic effects of medicines. This article provides an overview of the major APIs that are entered into antiretroviral therapy (ART), outlines how APIs are manufactured, and examines the regulatory and cost frameworks of manufacturi...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2897

    authors: Fortunak JM,de Souza RO,Kulkarni AA,King CL,Ellison T,Miranda LS

    更新日期:2014-01-01 00:00:00

  • Altered expression of nucleoside transporter genes (SLC28 and SLC29) in adipose tissue from HIV-1-infected patients.

    abstract:BACKGROUND:Nucleoside transporter proteins (NTs) encoded by members of the SLC28 and SLC29 gene families contribute to nucleoside and nucleobase recycling but also modulate extracellular adenosine levels and thus adenosine-regulated metabolic targets. METHODS:We have examined the expression pattern of NT-encoding gene...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Guallar JP,Cano-Soldado P,Aymerich I,Domingo JC,Alegre M,Domingo P,Villarroya F,Javier Casado F,Giralt M,Pastor-Anglada M

    更新日期:2007-01-01 00:00:00

  • The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study.

    abstract:BACKGROUND:Nucleoside (or nucleotide) reverse transcriptase inhibitors (NRTIs) cause side effects in some patients, prompting the use of either partly or fully NRTI-sparing regimens. METHODS:We used data from the Swiss HIV Cohort Study to estimate the effectiveness of two new dolutegravir dual regimens relative to the...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3310

    authors: Young J,Scherrer AU,Calmy A,Tarr PE,Bernasconi E,Cavassini M,Hachfeld A,Vernazza P,Günthard HF,Bucher HC,Swiss HIV Cohort Study.

    更新日期:2019-01-01 00:00:00

  • Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity.

    abstract:BACKGROUND:Antiviral and immune-modulating properties of low-molecular-weight heparin (LMWH) against coronaviridae have been reported by in vitro studies, but no in vivo evidence is yet available. We sought to know whether the timing of prophylactic doses of LMWH during the course of COVID-19 may affect the time to SAR...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3377

    authors: Trunfio M,Salvador E,Gaviraghi A,Audagnotto S,Marinaro L,Motta I,Casciaro R,Ghisetti V,Fava C,Bonora S,Di Perri G,Calcagno A,e-COVID Study Group.

    更新日期:2021-01-18 00:00:00

  • Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19.

    abstract::Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 is highly inf...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3362

    authors: Xie X,Jiang Y,Zeng Y,Liu H

    更新日期:2020-06-04 00:00:00

  • Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.

    abstract:OBJECTIVES:To assess potential pharmacokinetic (PK) interactions between atazanavir (ATV, 300 mg, once daily) and lopinavir (LPV, 400 mg, twice daily), both boosted by ritonavir (RTV, 100 mg). DESIGN:Two-parallel groups, addition of LPV in patients receiving ATV (n=6), and addition of ATV in patients receiving LPV (n=...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Colombo S,Buclin T,Franc C,Guignard N,Khonkarly M,Tarr PE,Rochat B,Biollaz J,Telenti A,Decosterd LA,Cavassini M

    更新日期:2006-01-01 00:00:00

  • Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013.

    abstract:BACKGROUND:US guidelines recommend genotyping for persons newly diagnosed with HIV infection to identify transmitted drug resistance mutations associated with decreased susceptibility to nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors. To date, testin...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2780

    authors: Stekler JD,McKernan J,Milne R,Tapia KA,Mykhalchenko K,Holte S,Maenza J,Stevens CE,Buskin SE,Mullins JI,Frenkel LM,Collier AC

    更新日期:2015-01-01 00:00:00

  • The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1.

    abstract:BACKGROUND:Current stopping rules during pegylated interferon (peg-IFN)/ribavirin (RBV) treatment rely on week 12 HCV RNA response, but earlier identification of non-responders offers clinical and economic advantages. AIMS AND METHODS:To evaluate, among 129 HCV-genotype-1-infected, treatment-naive patients receiving p...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Bárcena R,Moreno A,del Campo S,Muriel A,Mateos ML,Garrido E,García M,Quereda C,Moreno S,Moreno A

    更新日期:2007-01-01 00:00:00

  • Management of hepatitis B patients with antiviral resistance.

    abstract::Drug resistance is an expected consequence of antiviral therapy for chronic hepatitis B because of the high rate of hepatitis B virus (HBV) replication, the lack of proof-reading during reverse transcription of the pregenomic RNA and the low efficacy of available therapies in eliminating covalently closed circular HBV...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Fung SK,Lok AS

    更新日期:2004-12-01 00:00:00

  • Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.

    abstract::Clinical research has indicated that the use of nucleoside reverse transcriptase inhibitor (NRTI) and HIV protease inhibitor (PI) therapy is associated with a risk of long-term toxicity syndromes, and that the aetiopathogenesis of these adverse effects is independent of the antiretroviral effects of these drugs. In re...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Nolan D,John M,Mallal S

    更新日期:2001-09-01 00:00:00

  • Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception.

    abstract:BACKGROUND:Little is known about pregnancy patterns and levels of HIV RNA in HIV-infected women conceiving on highly active antiretroviral therapy (HAART) with non-suppressed viral load (VL), nor about their therapeutic management. METHODS:Linear mixed models were fitted to study changes in VL and potential associated...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:10.3851/IMP1489

    authors: European Collaborative Study.

    更新日期:2010-01-01 00:00:00

  • NS3 genetic variability in HCV genotype-1b isolates from liver specimens and blood samples of treatment-naive patients with chronic hepatitis C.

    abstract:BACKGROUND:Two distinct inhibitors of the HCV protease have been approved for the treatment of patients infected with HCV genotype-1. These drugs are highly efficient in suppressing HCV replication; however, their use is limited by the emergence of viral mutants resistant to them after a very short time of treatment. B...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2326

    authors: Maimone S,Musolino C,Squadrito G,Raffa G,Pollicino T,Raimondo G

    更新日期:2013-01-01 00:00:00

  • Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial.

    abstract:OBJECTIVE:A high level of adherence to antiretroviral therapy is required for complete suppression of HIV replication, immunological and clinical effectiveness. We investigated whether cognitive behaviour therapy can improve medication adherence. DESIGN:Prospective randomized 1-year trial. SETTING:Collaboration of HI...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Weber R,Christen L,Christen S,Tschopp S,Znoj H,Schneider C,Schmitt J,Opravil M,Günthard HF,Ledergerber B,Swiss HIV Cohort Study.

    更新日期:2004-02-01 00:00:00

  • Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV.

    abstract:BACKGROUND:Monocytes transmigrating to the brain play a central role in HIV neuropathology. We hypothesized that the continued existence of neurocognitive impairment (NCI) despite potent antiretroviral (ARV) therapy is mediated by the inability of such therapy to control this monocyte/macrophage reservoir. METHODS:Cro...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2411

    authors: Shikuma CM,Nakamoto B,Shiramizu B,Liang CY,DeGruttola V,Bennett K,Paul R,Kallianpur K,Chow D,Gavegnano C,Hurwitz SJ,Schinazi RF,Valcour VG

    更新日期:2012-01-01 00:00:00

  • A systematic review of a single-class maintenance strategy with nucleoside/nucleotide reverse transcriptase inhibitors in HIV/AIDS.

    abstract:BACKGROUND:Single-drug class regimens with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are generally not recommended as initial therapy because they are inferior compared with therapy with two NRTIs plus efavirenz. However, triple-NRTI combinations can be useful in specific circumstances such as in t...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,meta分析,评审

    doi:10.3851/IMP2726

    authors: Sprenger HG,Bierman WF,van der Werf TS,Gisolf EH,Richter C

    更新日期:2014-01-01 00:00:00

  • Activity of ergoferon against lethal influenza A (H3N2) virus infection in mice.

    abstract:BACKGROUND:The influenza A virus accounts for serious annual viral upper respiratory tract infections. It is constantly able to modify its antigenic structure, thus evading host defence mechanisms. Moreover, currently available anti-influenza agents have a rather limited application, emphasizing the further need for ne...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,收录出版

    doi:10.3851/IMP3115

    authors: Skarnovich MA,Emelyanova AG,Petrova NV,Borshcheva AA,Gorbunov EA,Mazurkov OY,Skarnovich MO,Tarasov SA,Shishkina LN,Epstein OI

    更新日期:2017-01-01 00:00:00

  • Transmitted, pre-treatment and acquired antiretroviral drug resistance among men who have sex with men and transgender women living with HIV in Nigeria.

    abstract:BACKGROUND:Across sub-Saharan Africa, men who have sex with men (MSM) and transgender women (TGW) have disproportionately poor HIV treatment outcomes. Stigma and criminalization create barriers to health-care engagement and adherence to antiretroviral therapy (ART), potentially promoting the development of HIV drug res...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3342

    authors: Crowell TA,Kijak GH,Sanders-Buell E,O'Sullivan AM,Kokogho A,Parker ZF,Lawlor J,Polyak CS,Adebajo S,Nowak RG,Baral SD,Robb ML,Charurat ME,Ake JA,Ndembi N,Tovanabutra S,TRUST\/RV368 Study Group.

    更新日期:2019-01-01 00:00:00

  • Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.

    abstract:BACKGROUND:Little is known about the efficacy, safety and tolerability of pegylated interferon plus ribavirin treatment in patients with chronic hepatitis Cvirus (HCV) infection and histologically proven fully established cirrhosis. We aimed here to evaluate the safety of this regimen in such patients and to identify b...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:

    authors: Roffi L,Colloredo G,Pioltelli P,Bellati G,Pozzpi M,Parravicini P,Bellia V,Del Poggio P,Fornaciari G,Ceriani R,Ramella G,Corradi C,Rossini A,Bruno S,Gruppo Epatologico Lombardo.

    更新日期:2008-01-01 00:00:00

  • Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals.

    abstract:BACKGROUND:Sexually transmitted acute hepatitis C among HIV-positive homosexual men has been noted as an emerging epidemic. METHODS:Forty-seven patients with mainly sexually acquired, acute hepatitis C were enrolled in this prospective, multicentre trial, and 36 of these patients were treated within the acute phase of...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Vogel M,Nattermann J,Baumgarten A,Klausen G,Bieniek B,Schewe K,Jessen H,Boesecke C,Rausch M,Lutz T,Fenske S,Schranzo D,Kümmerle T,Schuler C,Theisen A,Mayr C,Seidel T,Rockstroh JK

    更新日期:2006-01-01 00:00:00

  • Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus.

    abstract:BACKGROUND:Human cytomegalovirus (HCMV) infections remain a major problem in immunocompromised patients. Three antiviral agents, ganciclovir (GCV), foscarnet (FOS) and cidofovir (CDV), are currently approved for the treatment of HCMV infections. They all target the viral DNA polymerase and are associated with significa...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3028

    authors: Drouot E,Piret J,Boivin G

    更新日期:2016-01-01 00:00:00

  • Successful therapy of cyclosporin A in pityriasis lichenoides et varioliformis acuta preceded by hand, foot and mouth disease.

    abstract::To our knowledge, there are no previously published cases of enteroviral infection complicated by pityriasis lichenoides et varioliformis acuta (PLEVA). A 30-year-old woman is reported with a severe form of PLEVA, preceded by hand, foot and mouth disease. Immunosuppressive treatment with cyclosporin A resulted in rapi...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3012

    authors: Lis-Święty A,Michalska-Bańkowska A,Zielonka-Kucharzewska A,Pypłacz-Gumprecht A

    更新日期:2016-01-01 00:00:00

  • Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.

    abstract:BACKGROUND:Although antiretroviral therapy during pregnancy is associated with significant reductions in the risk of vertical transmission of HIV, attainment of this outcome in highly treatment-experienced pregnant women might be complicated by the lack of active drugs available to assemble a potent regimen. The recent...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1558

    authors: Jaworsky D,Thompson C,Yudin MH,Bitnun A,Brophy J,Samson L,Antoniou T,Loutfy MR

    更新日期:2010-01-01 00:00:00

  • A phase I/IIa study with succinylated human serum albumin (Suc-HSA), a candidate HIV-1 fusion inhibitor.

    abstract:BACKGROUND:Succinylated human serum albumin (Suc-HAS) is a negatively charged neo-glycoprotein that binds to the positively charged V3-loop of HIV-1 gp120, acting as HIV-1-fusion inhibitor in vitro (IC50: 0.5-5.0 microg/ml). Suc-HSA was safe in rats and monkeys, and showed antiretroviral effect in a human-to-mouse mode...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,随机对照试验

    doi:

    authors: Vermeulen JN,Meijer DK,Over J,Lange J,Proost JH,Bakker HI,Beljaars L,Wit FW,Prins JM

    更新日期:2007-01-01 00:00:00

  • Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2.0 and the Abbott RealTime hepatitis C assays - implications for response-guided therapy in genotype 1 infections.

    abstract:BACKGROUND:With the advent of the protease inhibitors boceprevir and telaprevir a novel therapy approach for HCV genotype 1 infected subjects has become standard of care. Quantification of HCV viral load (VL) represents an important predictor of treatment response. METHODS:Two different real-time PCR platforms, the CO...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2723

    authors: Taylor N,Haschke-Becher E,Greil R,Strasser M,Oberkofler H

    更新日期:2014-01-01 00:00:00

  • External quality assessment of HLA-B*5701 reporting: an international multicentre survey.

    abstract:OBJECTIVES:HLA-B*5701 strongly predicts abacavir hypersensitivity (HSR), but implementation of effective routine screening into clinical practice requires testing be practical and accurate. We tested the proficiency of HLA-B*5701 typing among laboratories using sequence-specific primer PCR. DESIGN AND METHODS:DNA pane...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:

    authors: Hammond E,Almeida CA,Mamotte C,Nolan D,Phillips E,Schollaardt TA,Gill MJ,Angel JB,Neurath D,Li J,Giulivi T,McIntyre C,Koultchitski G,Wong B,Reis M,Rachlis A,Cole DE,Chew CB,Neifer S,Lalonde R,Roger M,Jeanneau A

    更新日期:2007-01-01 00:00:00

  • Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice.

    abstract:BACKGROUND:Virological success (VS) and immunological reconstitution (IR) of antiretroviral-naive HIV-1-infected patients with pre-therapy viral load (VL) >500,000 copies/ml was assessed after 12 months of treatment according to initial drug-class regimens. METHODS:An observational multicentre retrospective study was ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3197

    authors: Santoro MM,Di Carlo D,Armenia D,Zaccarelli M,Pinnetti C,Colafigli M,Prati F,Boschi A,Antoni AMD,Lagi F,Sighinolfi L,Gervasoni C,Andreoni M,Antinori A,Mussini C,Perno CF,Borghi V,Sterrantino G

    更新日期:2018-01-01 00:00:00

  • Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART.

    abstract:BACKGROUND:Proton magnetic resonance spectroscopy (1H-MRS) and neuropsychological tests may be useful for monitoring the effectiveness of highly active antiretroviral therapy (HAART) in HIV-associated brain injury. We aimed to evaluate whether brain abnormalities will improve 3 months after HAART. METHOD:Thirty-three ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Chang L,Ernst T,Witt MD,Ames N,Walot I,Jovicich J,DeSilva M,Trivedi N,Speck O,Miller EN

    更新日期:2003-02-01 00:00:00